News Categories Inhaled Glycopyrronium Improves Lung Function in COPD Patients Phase II study evaluates once-daily, orally inhaled monotherapy (January 23) Positive results have been reported from a phase II study of PSX1002 (Prosonix) in patients with...
Buy This Photo New Bedford is the unhealthiest community in Massachusetts in which to grow old, according to the findings of a massive, year-long study of health and aging commissioned by the Tufts Health Plan Foundation. Where we rank While New Bedford doesn’t...
Background Tiotropium and long-acting beta2-agonists (LABAs) are both accepted in the routine management for people with stable chronic obstructive pulmonary disease (COPD). There are new studies which have compared tiotropium with LABAs, including some that have...
How much does it cost to develop a new drug? According to Joseph Dimasi of the Tufts Center for the Study of Drug Development, on average, the capitalized cost comes out to about $1.3 billion (adjusted to 2009 dollars). And a not-insignificant portion of these costs...
Jan. 23, 2014 — Reducing health inequalities and increasing life expectancy in the United States have both been primary goals of the national health initiative, Healthy People 2020. Unfortunately, according to a new study in the American Journal of Preventive...
First clinical data from PSX1002, a novel, orally inhaled, drug-only, pMDI suspension formulation of glycopyrronium bromide, a long-acting muscarinic antagonist (LAMA) Prosonix, an innovative speciality pharmaceutical company developing a portfolio of inhaled...
RSS Error: A feed could not be found at `http://www.scoop.it/t/pulmonaryrehabnews/rss.xml`; the status code is `404` and content-type is `text/html;charset=UTF-8`
